CD8A and neoplasm: A pre‐angiogenesis inhibitor strategy improves immune checkpoint inhibitor effects by improving CD8 infiltration and drug delivery.The current clinical protocol of administering AI and ICI on the same day results in ICI acting when vascular normalization is insufficient to mobilize CTL in the tumor tissue.